Cargando…
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
BACKGROUND: B7-H3, an immune-checkpoint molecule and a transmembrane protein, is overexpressed in non-small cell lung cancer (NSCLC), making it an attractive therapeutic target. Here, we aimed to systematically evaluate the value of B7-H3 as a target in NSCLC via T cells expressing B7-H3-specific ch...
Autores principales: | Liu, Jie, Yang, Shuo, Cao, Bihui, Zhou, Guangyu, Zhang, Fengjuan, Wang, Yuan, Wang, Rixin, Zhu, Lipeng, Meng, Ya, Hu, Cong, Liang, Hui, Lin, Xu, Zhu, Kangshun, Chen, Guokai, Luo, Kathy Qian, Di, Lijun, Zhao, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844995/ https://www.ncbi.nlm.nih.gov/pubmed/33514401 http://dx.doi.org/10.1186/s13045-020-01024-8 |
Ejemplares similares
-
Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
por: Yang, Shuo, et al.
Publicado: (2020) -
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014) -
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023) -
Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022) -
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)